Skip to main content
Genix Pharmaceuticals Corporation logo

Genix Pharmaceuticals Corporation — Investor Relations & Filings

Ticker · GENX ISIN · CA37232A1093 LEI · 52990086O9FPM8QVNI53 TSXV Manufacturing
Open in API
Filings indexed 136 across all filing types
Latest filing 2025-02-26 Management Reports
Country CA Canada
Listing TSXV GENX

About Genix Pharmaceuticals Corporation

https://genixpharm.com/

Genix Pharmaceuticals Corporation is an innovative life sciences company focused on the research, development, manufacturing, licensing, sales, and distribution of novel, branded, and generic products. The company operates as a formulator and marketer of life sciences-related products, specializing primarily in two key areas: nutraceuticals and ophthalmic solutions. Genix is committed to providing high-quality, affordable health solutions to patients through generic drugs, novel over-the-counter (OTC) products, and nutraceuticals. A core strategic focus is the prevention and management of chronic diseases, addressing conditions such as those associated with diabetes and hypertension.

Recent filings

Filing Released Lang Actions
Annual MD&A - English.pdf
Management Reports Classification · 1% confidence The document is titled "Management's Discussion and Analysis (MD&A) for the year ended October 31, 2024". It provides a narrative explanation of the company’s past performance, business overview, financial trends, risks, quarterly summaries, and outlook. This is exactly the scope of a Management Discussion & Analysis report. Therefore, it should be classified under Management Reports (Code: MDA).
2025-02-26 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 1% confidence The document is a completed statutory regulatory form (Form 13-501F1) filed with the Alberta Securities Commission to certify participation fee calculations. It is not an earnings announcement, annual or interim report, proxy, or any financial statement to investors, but rather a compliance filing under securities regulations. This falls under the generic Regulatory Filings category.
2025-02-26 English
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 1% confidence The document is titled “Independent Auditors’ Report” and contains the auditor’s opinion, basis for opinion, key audit matters, management responsibilities, audit scope and the audited financial statements (statements of financial position, comprehensive loss, cash flows, changes in equity and related notes) for the years ended October 31, 2024 and 2023. It does not include broader annual report sections such as MD&A, strategic review or corporate overview, so it is a standalone audit report. This matches the “Audit Report / Information” category. FY 2024
2025-02-26 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2024-09-20 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings
2024-09-20 English
Interim MD&A - English.pdf
Regulatory Filings
2024-09-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.